Zobrazeno 1 - 10
of 139
pro vyhledávání: '"John L Villano"'
Autor:
Catherine R Garcia, Stacey A Slone, Thomas Pittman, William H St Clair, Donita D Lightner, John L Villano
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0203639 (2018)
BACKGROUND:Low-grade gliomas affect younger adults and carry a favorable prognosis. They include a variety of biological features affecting clinical behavior and treatment. Having no guidelines on treatment established, we aim to describe clinical an
Externí odkaz:
https://doaj.org/article/4fb5daf4267748699f6e528a44bd46dd
Autor:
Andre Ene, Jing Di, Janna H. Neltner, Thomas Pittman, Susanne M. Arnold, Jill M. Kolesar, John L. Villano, Sara E. Bachert, Derek B. Allison
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundEWSR1::PATZ1 fusion tumors are exceedingly rare in the central nervous system with only 14 prior cases documented. PATZ1 fusion neuroepithelial tumors are beginning to be recognized as a distinct molecular class of neoplasms that most often
Externí odkaz:
https://doaj.org/article/283b85944cbb434a9576dffac41b0fb1
Autor:
Menghan Wang, Tianxin Yu, Jinpeng Liu, Li Chen, Arnold J. Stromberg, John L. Villano, Susanne M. Arnold, Chunming Liu, Chi Wang
Publikováno v:
BMC Bioinformatics, Vol 20, Iss 1, Pp 1-12 (2019)
Abstract Background Cancer arises through accumulation of somatically acquired genetic mutations. An important question is to delineate the temporal order of somatic mutations during carcinogenesis, which contributes to better understanding of cancer
Externí odkaz:
https://doaj.org/article/76271ca4c7004e37874b957050ceb424
Autor:
Benjamin B. Morris, Jason P. Smith, Qi Zhang, Zhijie Jiang, Oliver A. Hampton, Michelle L. Churchman, Susanne M. Arnold, Dwight H. Owen, Jhanelle E. Gray, Patrick M. Dillon, Hatem H. Soliman, Daniel G. Stover, Howard Colman, Arnab Chakravarti, Kenneth H. Shain, Ariosto S. Silva, John L. Villano, Michael A. Vogelbaum, Virginia F. Borges, Wallace L. Akerley, Ryan D. Gentzler, Richard D. Hall, Cindy B. Matsen, C. M. Ulrich, Andrew R. Post, David A. Nix, Eric A. Singer, James M. Larner, Peter Todd Stukenberg, David R. Jones, Marty W. Mayo
Publikováno v:
Biomolecules, Vol 12, Iss 11, p 1570 (2022)
In the past decade, defective DNA repair has been increasingly linked with cancer progression. Human tumors with markers of defective DNA repair and increased replication stress exhibit genomic instability and poor survival rates across tumor types.
Externí odkaz:
https://doaj.org/article/df3f2dd332a741889c5d48abf7420c89
Autor:
Linda M. Liau, Keyoumars Ashkan, David D. Tran, Jian L. Campian, John E. Trusheim, Charles S. Cobbs, Jason A. Heth, Michael Salacz, Sarah Taylor, Stacy D. D’Andre, Fabio M. Iwamoto, Edward J. Dropcho, Yaron A. Moshel, Kevin A. Walter, Clement P. Pillainayagam, Robert Aiken, Rekha Chaudhary, Samuel A. Goldlust, Daniela A. Bota, Paul Duic, Jai Grewal, Heinrich Elinzano, Steven A. Toms, Kevin O. Lillehei, Tom Mikkelsen, Tobias Walbert, Steven R. Abram, Andrew J. Brenner, Steven Brem, Matthew G. Ewend, Simon Khagi, Jana Portnow, Lyndon J. Kim, William G. Loudon, Reid C. Thompson, David E. Avigan, Karen L. Fink, Francois J. Geoffroy, Scott Lindhorst, Jose Lutzky, Andrew E. Sloan, Gabriele Schackert, Dietmar Krex, Hans-Jorg Meisel, Julian Wu, Raphael P. Davis, Christopher Duma, Arnold B. Etame, David Mathieu, Santosh Kesari, David Piccioni, Manfred Westphal, David S. Baskin, Pamela Z. New, Michel Lacroix, Sven-Axel May, Timothy J. Pluard, Victor Tse, Richard M. Green, John L. Villano, Michael Pearlman, Kevin Petrecca, Michael Schulder, Lynne P. Taylor, Anthony E. Maida, Robert M. Prins, Timothy F. Cloughesy, Paul Mulholland, Marnix L. Bosch
Publikováno v:
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-9 (2018)
Abstract Background Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard therapy for newly di
Externí odkaz:
https://doaj.org/article/7b4a8b2c7d344b0e9344d197a7338b0a
Autor:
Meng Liu, Jigisha P. Thakkar, Catherine R. Garcia, Therese A. Dolecek, Lars M. Wagner, Emily Van Meter Dressler, John L. Villano
Publikováno v:
Cancer Medicine, Vol 7, Iss 4, Pp 1151-1159 (2018)
Abstract Glioblastoma in children is an aggressive disease with no defined standard therapy. We evaluated hospital‐based demographic and survival patterns obtained through the National Cancer Database to better characterize children with glioblasto
Externí odkaz:
https://doaj.org/article/d8cfb69575154f4587a563fb0e888ed5
Autor:
Christina I. Tsien, Stephanie L. Pugh, Adam P. Dicker, Jeffrey J. Raizer, Martha M. Matuszak, Enrico C. Lallana, Jiayi Huang, Ozer Algan, Nimisha Deb, Lorraine Portelance, John L. Villano, John T. Hamm, Kevin S. Oh, Arif N. Ali, Michelle M. Kim, Scott M. Lindhorst, Minesh P. Mehta
PURPOSE To assess whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free survival (PFS), compared with BEV alone in recurrent glioblastoma (GBM). The primary objective was OS, and secondar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a4c03b0f137d718334db45ae38b7cb4
https://www.zora.uzh.ch/id/eprint/228975/
https://www.zora.uzh.ch/id/eprint/228975/
Autor:
Connor Willis, Hillevi Bauer, Trang H. Au, Jyothi Menon, Sudhir Unni, Dao Tran, Zachary Rivers, Wallace Akerley, Matthew B. Schabath, Firas Badin, Ashley Sekhon, Malini Patel, Bing Xia, Beth Gustafson, John L. Villano, John-Michael Thomas, Solomon J. Lubinga, Michael A. Cantrell, Diana Brixner, David Stenehjem
Publikováno v:
Oncotarget
Background: Tumor mutational burden (TMB) is a potential biomarker to predict tumor response to immuno-oncology agents in patients with metastatic non-small cell lung cancer (NSCLC). Materials and Methods: A multi-site cohort study evaluated patients
Autor:
Rachael M. Morgan, Zin W. Myint, Rani Jayswal, Heidi L. Weiss, Allison R Butts, John L. Villano, Catherine R Garcia, Chi Wang
Publikováno v:
J Neurooncol
Background Hematological adverse events (HAEs) are common during treatment for glioblastoma (GBM), usually associated with temozolomide (TMZ). Their clinical value is uncertain, as few investigations have focused on outcomes for HAEs during GBM treat
Autor:
Linda M. Liau, Keyoumars Ashkan, Steven Brem, Jian L. Campian, John E. Trusheim, Fabio M. Iwamoto, David D. Tran, George Ansstas, Charles S. Cobbs, Jason A. Heth, Michael E. Salacz, Stacy D’Andre, Robert D. Aiken, Yaron A. Moshel, Joo Y. Nam, Clement P. Pillainayagam, Stephanie A. Wagner, Kevin A. Walter, Rekha Chaudhary, Samuel A. Goldlust, Ian Y. Lee, Daniela A. Bota, Heinrich Elinzano, Jai Grewal, Kevin Lillehei, Tom Mikkelsen, Tobias Walbert, Steven Abram, Andrew J. Brenner, Matthew G. Ewend, Simon Khagi, Darren S. Lovick, Jana Portnow, Lyndon Kim, William G. Loudon, Nina L. Martinez, Reid C. Thompson, David E. Avigan, Karen L. Fink, Francois J. Geoffroy, Pierre Giglio, Oleg Gligich, Dietmar Krex, Scott M. Lindhorst, Jose Lutzky, Hans-Jörg Meisel, Minou Nadji-Ohl, Lhagva Sanchin, Andrew Sloan, Lynne P. Taylor, Julian K. Wu, Erin M. Dunbar, Arnold B. Etame, Santosh Kesari, David Mathieu, David E. Piccioni, David S. Baskin, Michel Lacroix, Sven-Axel May, Pamela Z. New, Timothy J. Pluard, Steven A. Toms, Victor Tse, Scott Peak, John L. Villano, James D. Battiste, Paul J. Mulholland, Michael L. Pearlman, Kevin Petrecca, Michael Schulder, Robert M. Prins, Alton L. Boynton, Marnix L. Bosch
Publikováno v:
JAMA oncology.
ImportanceGlioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed.ObjectiveTo investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to st